Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

S O Dolly; AJ Wagner; JC Bendell; HL Kindler; L M Krug; T Y Seiwert; M G Zauderer; Martijn Lolkema; D Apt; R F Yeh; J O Fredrickson; J M Spoerke; H Koeppen; J A Ware; J O Lauchle; HA Burris; JS de Bono

doi:10.1158/1078-0432.ccr-15-2225

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

S O Dolly, AJ Wagner, JC Bendell, HL Kindler, L M Krug, T Y Seiwert, M G Zauderer, Martijn Lolkema, D Apt, R F Yeh, J O Fredrickson, J M Spoerke, H Koeppen, J A Ware, J O Lauchle, HA Burris, JS de Bono

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

81 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2874-2884
Number of pages	11
Journal	Clinical Cancer Research
Volume	22
Issue number	12
DOIs	https://doi.org/10.1158/1078-0432.ccr-15-2225
Publication status	Published - 2016

Access to Document

10.1158/1078-0432.ccr-15-2225

Cite this

Dolly, S. O., Wagner, AJ., Bendell, JC., Kindler, HL., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M., Apt, D., Yeh, R. F., Fredrickson, J. O., Spoerke, J. M., Koeppen, H., Ware, J. A., Lauchle, J. O., Burris, HA., & de Bono, JS. (2016). Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 22(12), 2874-2884. https://doi.org/10.1158/1078-0432.ccr-15-2225

@article{a8fc8ca877e14126b1de73ab22b7c1bd,

title = "Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors",

author = "Dolly, {S O} and AJ Wagner and JC Bendell and HL Kindler and Krug, {L M} and Seiwert, {T Y} and Zauderer, {M G} and Martijn Lolkema and D Apt and Yeh, {R F} and Fredrickson, {J O} and Spoerke, {J M} and H Koeppen and Ware, {J A} and Lauchle, {J O} and HA Burris and {de Bono}, JS",

year = "2016",

doi = "10.1158/1078-0432.ccr-15-2225",

language = "Undefined/Unknown",

volume = "22",

pages = "2874--2884",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "12",

}

Dolly, SO, Wagner, AJ, Bendell, JC, Kindler, HL, Krug, LM, Seiwert, TY, Zauderer, MG, Lolkema, M, Apt, D, Yeh, RF, Fredrickson, JO, Spoerke, JM, Koeppen, H, Ware, JA, Lauchle, JO, Burris, HA & de Bono, JS 2016, 'Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors', Clinical Cancer Research, vol. 22, no. 12, pp. 2874-2884. https://doi.org/10.1158/1078-0432.ccr-15-2225

TY - JOUR

T1 - Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

AU - Dolly, S O

AU - Wagner, AJ

AU - Bendell, JC

AU - Kindler, HL

AU - Krug, L M

AU - Seiwert, T Y

AU - Zauderer, M G

AU - Lolkema, Martijn

AU - Apt, D

AU - Yeh, R F

AU - Fredrickson, J O

AU - Spoerke, J M

AU - Koeppen, H

AU - Ware, J A

AU - Lauchle, J O

AU - Burris, HA

AU - de Bono, JS

PY - 2016

Y1 - 2016

U2 - 10.1158/1078-0432.ccr-15-2225

DO - 10.1158/1078-0432.ccr-15-2225

M3 - Article

VL - 22

SP - 2874

EP - 2884

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -